Physician profile
Lin Wang
NPI 1366974859
$618.47
in general payments reported to CMS, 2019-2025
12 companies · $272 in 2025
The $272 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $97.93 · 2024: $249 · 2025: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $574 · Education: $44.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $574.24 |
| Education | $44.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $206.51 | 2024-2025 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $87.37 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $67.95 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $45.54 | 2023 | Lokelma, Farxiga |
| Gastroklenz, INC. Dba Cloudcath | $35.46 | 2024 | |
| Ascendis Pharma Endocrinology INC | $29.40 | 2025 | Yorvipath |
| Scpharmaceuticals INC. | $26.43 | 2025 | |
| Calliditas Therapeutics US INC. | $24.85 | 2024 | |
| Merck Sharp & Dohme LLC | $24.82 | 2023 | Keytruda |
| Akebia Therapeutics INC | $24.61 | 2024 | Vafseo |
| Opko Pharmaceuticals, LLC | $24.41 | 2024 | Rayaldee |
| Aurinia Pharma U.S., INC. | $21.12 | 2025 | Lupkynis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lin Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.